UNLABELLED: PET using 18F-fluorodeoxyglucose (FDG) is increasingly applied to monitor the response of malignant tumors to radiotherapy and chemotherapy. The aim of this study was to assess the reproducibility of serial FDG PET measurements to define objective criteria for the evaluation of treatment-induced changes. METHODS: Sixteen patients participating in phase I studies of novel antineoplastic compounds were examined twice by FDG PET within 10 d while they were receiving no therapy. Standardized uptake values (SUVs), FDG net influx constants (Ki), glucose normalized SUVs (SUV(gluc)) and influx constants (K(i,gluc)) were determined for 50 separate lesions. The precision of repeated measurements was determined on a lesion-by-lesion and a patient-by-patient basis. RESULTS: None of the parameters showed a significant increase or decrease at the two examinations. The differences of repeated measurements were approximately normally distributed for all parameters with an SD of the mean percentage difference of about 10%. The 95% normal ranges for spontaneous fluctuations of SUV, SUV(gluc), Ki and K(i,gluc) were determined to be +/-0.91, +/-1.14, +/-0.52 mL/100 g/min and +/-0.64 mL/100 g/min, respectively. Analysis on a lesion-by-lesion basis yielded similar results. CONCLUSION: FDG PET provides several highly reproducible quantitative parameters of tumor glucose metabolism. Changes of a parameter that are outside the 95% normal range determined in this study may be used to define a metabolic response to therapy.
UNLABELLED: PET using 18F-fluorodeoxyglucose (FDG) is increasingly applied to monitor the response of malignant tumors to radiotherapy and chemotherapy. The aim of this study was to assess the reproducibility of serial FDG PET measurements to define objective criteria for the evaluation of treatment-induced changes. METHODS: Sixteen patients participating in phase I studies of novel antineoplastic compounds were examined twice by FDG PET within 10 d while they were receiving no therapy. Standardized uptake values (SUVs), FDG net influx constants (Ki), glucose normalized SUVs (SUV(gluc)) and influx constants (K(i,gluc)) were determined for 50 separate lesions. The precision of repeated measurements was determined on a lesion-by-lesion and a patient-by-patient basis. RESULTS: None of the parameters showed a significant increase or decrease at the two examinations. The differences of repeated measurements were approximately normally distributed for all parameters with an SD of the mean percentage difference of about 10%. The 95% normal ranges for spontaneous fluctuations of SUV, SUV(gluc), Ki and K(i,gluc) were determined to be +/-0.91, +/-1.14, +/-0.52 mL/100 g/min and +/-0.64 mL/100 g/min, respectively. Analysis on a lesion-by-lesion basis yielded similar results. CONCLUSION:FDG PET provides several highly reproducible quantitative parameters of tumor glucose metabolism. Changes of a parameter that are outside the 95% normal range determined in this study may be used to define a metabolic response to therapy.
Authors: Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske Journal: Eur J Nucl Med Mol Imaging Date: 2003-12 Impact factor: 9.236
Authors: Daniel C Sullivan; Nancy A Obuchowski; Larry G Kessler; David L Raunig; Constantine Gatsonis; Erich P Huang; Marina Kondratovich; Lisa M McShane; Anthony P Reeves; Daniel P Barboriak; Alexander R Guimaraes; Richard L Wahl Journal: Radiology Date: 2015-08-12 Impact factor: 11.105
Authors: Albert Wu; Huaiyu Zheng; Jennifer Kraenzle; Ashley Biller; Carol D Vanover; Mary Proctor; Leslie Sherwood; Marlene Steffen; Chin Ng; Daniel J Mollura; Colleen B Jonsson Journal: ILAR J Date: 2012
Authors: Robert L Harrison; Brian F Elston; Robert K Doot; Thomas K Lewellen; David A Mankoff; Paul E Kinahan Journal: Transl Oncol Date: 2014-02-01 Impact factor: 4.243
Authors: Lotte Nygård; Marianne C Aznar; Barbara M Fischer; Gitte F Persson; Charlotte B Christensen; Flemming L Andersen; Mirjana Josipovic; Seppo W Langer; Andreas Kjær; Ivan R Vogelius; Søren M Bentzen Journal: Am J Nucl Med Mol Imaging Date: 2018-04-25
Authors: Yusuf Menda; Laura L Boles Ponto; Michael K Schultz; Gideon K D Zamba; G Leonard Watkins; David L Bushnell; Mark T Madsen; John J Sunderland; Michael M Graham; Thomas M O'Dorisio; M Sue O'Dorisio Journal: Pancreas Date: 2013-08 Impact factor: 3.327
Authors: Paul E Kinahan; Robert K Doot; Michelle Wanner-Roybal; Luc M Bidaut; Samuel G Armato; Charles R Meyer; Geoffrey McLennan Journal: Transl Oncol Date: 2009-12 Impact factor: 4.243